B.Riley Financial Keeps Their Hold Rating on Madrigal Pharmaceuticals (MDGL)
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research ...
B.Riley Financial Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...
B.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of ...
Business Insider27d
Centessa Pharmaceuticals: Promising Market Position and Growth Potential in Orexin Agonists for Narcolepsy
In a report released yesterday, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Centessa Pharmaceuticals (CNTA – Research Report), with a price target of $33.00. Discover the ...
Analysts Conflicted on These Healthcare Names: Ironwood Pharma (IRWD) and Centessa Pharmaceuticals (CNTA)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ironwood Pharma (IRWD – Research Report) and ...
Business Insider23d
Denali Therapeutics: Strategic Pipeline Potential and Investment Opportunity Amid Recent Setbacks
Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at $38.00. Discover outperforming stocks and ...
Business Insider23d
Promising Potential for Agenus in Oncology: Buy Rating Reinforced by Strong CRC and Gastric Cancer Therapy Prospects
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Agenus (AGEN – Research Report) today and set a price target of $11.00. Discover outperforming stocks and invest smarter with ...
Business Insider1mon
Arrowhead Pharmaceuticals: Positioned for Growth with Strategic Partnerships and siRNA Advancements
In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a price target of $51.00. Pick the best ...
Business Insider27d
Arrowhead Pharmaceuticals: Strong Growth Potential Backed by siRNA Therapeutics and Financial Stability
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) yesterday and set a price target of $51.00. Discover the latest stocks ...
Analysts Are Bullish on These Healthcare Stocks: Monopar Therapeutics Inc (MNPR), Nektar Therapeutics (NKTR)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monopar Therapeutics Inc (MNPR – Research ...
Business Insider1mon
Trevi Therapeutics’ Positive HAP Study Results and Market Potential Drive Buy Rating
B.Riley Financial analyst Mayank Mamtani has reiterated their bullish stance on TRVI stock, giving a Buy rating on November 18. Don't Miss our Black Friday Offers: Unlock your investing potential ...
Business Insider1mon
B.Riley Financial Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target of $109.00. The company’s shares opened today at ...